fosinopril has been researched along with leflunomide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Liu, X; Lou, T; Shi, C; Tang, H; Wang, C; Yin, P; Yu, X | 1 |
| Craig, JC; Hahn, D; Hodson, EM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for fosinopril and leflunomide
| Article | Year |
|---|---|
Interventions for preventing and treating kidney disease in IgA vasculitis.
Topics: Adult; Child; Fosinopril; Humans; IgA Vasculitis; Kidney Diseases; Leflunomide; Proteinuria; Tacrolimus; Vasculitis | 2023 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fosinopril and leflunomide
| Article | Year |
|---|---|
Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Female; Fosinopril; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Isoxazoles; Leflunomide; Male; Middle Aged | 2006 |
2 other study(ies) available for fosinopril and leflunomide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |